Comments
Johnson & Johnson plans $600 million charge linked to Risperdal sales
09.06.2012. | (Reuters) - Johnson & Johnson said on Friday it expects to take a special charge of about $600 million in the second quarter to bolster reserves for a potential settlement of civil lawsuits related to how it marketed schizophrenia treatment Risperdal and other drugs....
